March 18, 2008 16:30 ET

Eden Bioscience Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

BOTHELL, WA--(Marketwire - March 18, 2008) - Eden Bioscience Corporation (NASDAQ: EDEN) today announced that it has received a letter from the Nasdaq Stock Market notifying it that the closing bid price per share of the Company's common stock was above the $1.00 minimum bid price for 10 consecutive trading days and that, as a result, the Company has regained compliance with Nasdaq's minimum bid price requirement.

About Eden Bioscience

Eden Bioscience's business strategy is to sell harpin protein-based products to the home and garden market and use its available cash and any revenue generated from its home and garden business to explore whether there may be opportunities to realize potential value from its remaining business assets, primarily its tax loss carryforwards. Our headquarters are at 11816 North Creek Parkway N., Bothell, WA 98011-8201, 425-806-7300;

Contact Information

    Bradley S. Powell
    Eden Bioscience
    fax: 425-806-7400
    Email Contact